Cargando…

Using interferon-beta to combat cancer stem cell properties in triple negative breast cancer

Detalles Bibliográficos
Autores principales:	Doherty, Mary R., Jackson, Mark W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6049314/ https://www.ncbi.nlm.nih.gov/pubmed/30035180 http://dx.doi.org/10.18632/oncoscience.438

Ejemplares similares

Interferon-beta represses cancer stem cell properties in triple-negative breast cancer
por: Doherty, Mary R., et al.
Publicado: (2017)

The opposing effects of interferon-beta and oncostatin-M as regulators of cancer stem cell plasticity in triple-negative breast cancer
por: Doherty, Mary R., et al.
Publicado: (2019)

Triple-Negative Breast Cancer
por: Chu, Quyen D., et al.
Publicado: (2012)

Bioactive nanotherapeutic trends to combat triple negative breast cancer
por: Chowdhury, Pallabita, et al.
Publicado: (2021)

Metronomic chemotherapy for triple negative breast cancer?
por: Di Desidero, Teresa, et al.
Publicado: (2016)

Stratifying the stratifiers of triple negative breast cancer
por: Wang, Dong-Yu, et al.
Publicado: (2020)

Stratifying triple-negative breast cancer: which definition(s) to use?
por: Adamo, Barbara, et al.
Publicado: (2011)

Triple negative breast cancer: A continuing challenge
por: Gupta, Sudeep
Publicado: (2013)

Targeting MYC for triple-negative breast cancer treatment
por: Klauber-DeMore, Nancy, et al.
Publicado: (2018)

Sacituzumab govitecan in triple-negative breast cancer
por: de Nonneville, Alexandre, et al.
Publicado: (2022)

Neoadjuvant immunotherapy in early-stage triple negative breast cancer
por: Laouris, Panayiotis, et al.
Publicado: (2023)

The Adipokine Visfatin Modulates Cancer Stem Cell Properties in Triple-Negative Breast Cancer
por: Chiang, Yi-Fen, et al.
Publicado: (2023)

Achilles' heel of triple negative cancer
por: Ocaña, Alberto, et al.
Publicado: (2014)

Achilles' heel of triple negative cancer
por: Ocaña, Alberto, et al.
Publicado: (2014)

Targeting Cancer Stem Cells in Triple-Negative Breast Cancer
por: Park, So-Yeon, et al.
Publicado: (2019)

Regulation of cancer stem cells in triple negative breast cancer
por: Fultang, Norman, et al.
Publicado: (2021)

CXCR2 Small-Molecule Antagonist Combats Chemoresistance and Enhances Immunotherapy in Triple-Negative Breast Cancer
por: Ghallab, Alaa M., et al.
Publicado: (2022)

Combating CHK1 resistance in triple negative breast cancer: EGFR inhibition as potential combinational therapy
por: Stefanski, Casey D., et al.
Publicado: (2022)

Sacituzumab govitecan: ascending the treatment algorithm in triple negative breast cancer
por: Rozenblit, Mariya, et al.
Publicado: (2022)

Targeted therapy for metastatic triple negative breast cancer: The next frontier in precision oncology
por: Vidula, Neelima, et al.
Publicado: (2017)

Outcome for triple negative breast cancer in a retrospective cohort with an emphasis on response to platinum-based neoadjuvant therapy
por: Walsh, Elaine M., et al.
Publicado: (2018)

GSK3β regulates epithelial-mesenchymal transition and cancer stem cell properties in triple-negative breast cancer
por: Vijay, Geraldine Vidhya, et al.
Publicado: (2019)

The Triple-Negative Breast Cancer Database: an omics platform for reference, integration and analysis of triple-negative breast cancer data
por: Raju, Rajesh, et al.
Publicado: (2014)

Triple-negative breast cancer
por: Chacón, Reinaldo D, et al.
Publicado: (2010)

MYC promotes immune-suppression in triple-negative breast cancer via inhibition of interferon signaling
por: Zimmerli, Dario, et al.
Publicado: (2022)

The Role of Breast Cancer Stem Cells in Chemoresistance and Metastasis in Triple-Negative Breast Cancer
por: He, Lin, et al.
Publicado: (2021)

Targeting BCL6 and STAT3 in triple negative breast cancer: the one-two punch?
por: Walker, Sarah R., et al.
Publicado: (2015)

Novel Biomarkers to Guide Immunotherapy De-Escalation in the Neoadjuvant Setting in Triple-Negative Breast Cancer
por: Gandhi, Shipra
Publicado: (2023)

Estrogen receptor-beta is a potential target for triple negative breast cancer treatment
por: Austin, David, et al.
Publicado: (2018)

Estrogen receptor beta expression in triple negative breast cancers is not associated with recurrence or survival
por: Takano, Elena A., et al.
Publicado: (2023)

Prognostic Value of Cancer Stem Cells Markers in Triple-Negative Breast Cancer
por: Collina, Francesca, et al.
Publicado: (2015)

Challenges for Triple Negative Breast Cancer Treatment: Defeating Heterogeneity and Cancer Stemness
por: Mahmoud, Rinad, et al.
Publicado: (2022)

Evaluation of Breast Cancer Stem Cells and Intratumor Stemness Heterogeneity in Triple-negative Breast Cancer as Prognostic Factors
por: Yang, Fang, et al.
Publicado: (2016)

Transforming growth factor beta receptor type III is a tumor promoter in mesenchymal-stem like triple negative breast cancer
por: Jovanović, Bojana, et al.
Publicado: (2014)

Characteristics of triple-negative breast cancer
por: de Ruijter, Tim C., et al.
Publicado: (2010)

Triple Negative Breast Cancer – An Overview
por: Aysola, Kartik, et al.
Publicado: (2013)

Male Triple-Negative Breast Cancer
por: Qavi, Qasif, et al.
Publicado: (2021)

Immunotherapy for Triple-Negative Breast Cancer
por: Cao, Yifeng, et al.
Publicado: (2021)

Theranostics for Triple-Negative Breast Cancer
por: Choi, Hyeryeon, et al.
Publicado: (2023)

Lupeol synergizes with 5-fluorouracil to combat c-MET/EphA2 mediated chemoresistance in triple negative breast cancer
por: Mitra, Debarpan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_8br3dhkrca6ktpmohl6jq3363r